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Background/Aims: We investigated the concordance rate of the classification of 
polymyositis (PM) and dermatomyositis (DM) between the Bohan and Peter cri-
teria and the 2017 European League Against Rheumatism (EULAR)/American 
College of Rheumatology (ACR) classification criteria for idiopathic inflammatory 
myopathies (IIMs) (the 2017 EULAR/ACR criteria) in Korean patients. 
Methods: We retrospectively reviewed the medical records of 137 patients with PM 
and DM. We finally included 72 PM patients and 49 DM patients who fulfilled the 
Bohan and Peter criteria for PM and DM and reclassified them by the 2017 EU-
LAR/ACR criteria. 
Results: Three patients (4.2%) with probable PM were newly reclassified as non-
IIM due to a total score of 5.3 or smaller. Meanwhile, one patient with possible PM 
was newly reclassified as probable PM due to the presence of dysphagia. In addi-
tion, eight patients (16.3%) with possible DM with DM-specific typical skin rash 
were newly reclassified as amyopathic DM (ADM) due to the absence of proximal 
muscle weakness. The concordance rate of the classification between the Bohan 
and Peter criteria and the 2017 EULAR/ACR criteria was 95.8% for PM patients 
and 83.7% for DM patients. 
Conclusions: The Bohan and Peter criteria were comparable to the 2017 EULAR/
ACR criteria for classifying PM and DM in Korean patients. Considering the con-
venience of the Bohan and Peter criteria in the real clinical settings, we suggest 
that the old criteria should be preferentially applied and then performing muscle 
biopsy should be considered in a patient suspected of PM without antihistidyl 
tRNA synthetase (anti-Jo-1). Moreover, we suggest that ADM could also clinically 
be classified by the old criteria.
Keywords: Polymyositis; Dermatomyositis; Idiopathic inflammatory myopathy
Reclassification of Korean patients with polymyo-
sitis and dermatomyositis based on the Bohan and 
Peter criteria by the 2017 European League Against 
Rheumatism/American College of Rheumatology 
classification criteria for adult and juvenile idio-
pathic inflammatory myopathies 
Juyoung Yoo1, Sung Soo Ahn1, Seung Min Jung1, Jason Jungsik Song1,2, Yong-Beom Park1,2, and  
Sang-Won Lee1,2
442 www.kjim.org https://doi.org/10.3904/kjim.2019.149
The Korean Journal of Internal Medicine Vol. 36, No. 2, March 2021
INTRODUCTION
Idiopathic inflammatory myopathies (IIMs) are a group 
of chronic autoimmune diseases which are character-
ised by muscle weakness and various related symptoms. 
IIM can be classified into several subgroups according 
to typical clinical manifestations and histological find-
ings, such as polymyositis (PM), dermatomyositis (DM) 
and inclusion body myositis (IBM) [1]. PM often presents 
proximal muscle weakness, neck flexor muscle weakness 
and dysphagia [2]. Meanwhile, DM is classified based on 
DM-specific typical skin rashes such as heliotrope rash 
and Gottron’s papule or histological features with proxi-
mal muscle weakness. DM without muscle involvement 
is called amyopathic DM (ADM) [3]. DM occurs in both 
children and adults, whereas PM predominantly occurs 
in elder adults [4]. The incidence of IIM was reported to 
range from 5 to 7.4 cases per million populations and it 
has been increasing in recent years [5,6]. 
So far, several classification criteria for IIM have been 
suggested and the classification criteria for PM and 
DM proposed by Bohan and Peter in 1975 (the Bohan 
and Peter criteria) have widely been used among them 
[7,8]. The Bohan and Peter criteria consist of five items: 
(1) symmetrical weakness, usually progressive, of the 
limb-girdle muscles; (2) elevation of skeletal muscle en-
zyme levels; (3) abnormal electromyography results; (4) 
muscle biopsy abnormalities; (5) typical skin rash of DM. 
Definite PM can be classified when all first four items 
are met, whereas definite DM can be classified when 
DM-specific typical skin rash plus three of other items 
are met [7,8]. 
However, the Bohan and Peter criteria have several 
limitations such as a monocentric data based on clinical 
observation, no detailed mention of typical DM rash-
es, biopsy findings or myositis-specific autoantibod-
ies. Moreover, they have no instruction for exclusion 
or sub-classification. It is difficult to differentiate IIM 
from other medical conditions including peripheral 
neurological diseases and muscular dystrophies, and in 
particular, they could not discriminate between PM and 
IBM [9,10]. To overcome these limitations, the 2017 Eu-
ropean League Against Rheumatism (EULAR)/American 
College of Rheumatology (ACR) classification criteria for 
adult and juvenile idiopathic inflammatory myopathies 
(the 2017 EULAR/ACR criteria) were recently established. 
The 2017 EULAR/ACR criteria are based on the scoring 
system and a score of < 5.3 may rule out IIM (non-IIM) 
[11]. Nevertheless, the Bohan and Peter criteria are still 
being used for classifying IIM due to the small number 
of items and convenience in the real clinical settings. 
For this reason, we wondered whether we should apply 
the new criteria to all patients suspected of IIM instead 
of the Bohan and Peter criteria. Till now, there was no 
report on the concordance rate of the classification of 
PM and DM between the Bohan and Peter criteria and 
the 2017 EULAR/ACR criteria in Korean patients. Hence, 
in this study, we applied the 2017 EULAR/ACR criteria to 
Korean patients with PM and DM, who were classified 
by the Bohan and Peter criteria at diagnosis, and investi-
gated the concordance rate of the classification between 
the two criteria. 
METHODS
We retrospectively reviewed the medical records of 137 
patients with IIM, which were identified in the 10th 
revised International Classification Diseases (ICD-10), 
and included 121 patients with IIM (72 PM patients and 
49 DM patients) in this study. Sixteen patients with 
IIM were excluded due to insufficient medical records. 
Among 72 PM patients, 55 patients were classified as 
definite PM, 16 patients as probable PM and one patient 
as possible PM. Among 49 DM patients, 41 DM patients 
were diagnosed as definite DM and eight patients were 
as possible DM (Fig. 1). All patients had been first classi-
fied as PM and DM at the Department of Internal Med-
icine, Yonsei University College of Medicine, Severance 
Hospital, from January 2005 to September 2018. All pa-
tients fulfilled the Bohan and Peter criteria for PM and 
DM and had ever received glucocorticoid and/or im-
munosuppressive drugs for IIM, which were verified by 
the Korean Drug Utilisation Review system. All patients 
underwent neuromuscular examination by neurologists 
and had the results of anti-Jo-1 and serum muscle en-
zymes at diagnosis. We reclassified 72 PM patients and 
49 DM patients based on the Bohan and Peter criteria 
by the 2017 EULAR/ACR criteria using an online web 
calculator (www.imm.Kise/biostatistics/calculators/iim) 
and investigated the concordance rate of the classifica-
tion between the two criteria. This study was approved 
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by the Institutional Review Board of Severance Hospital 
(4-2018-1089), who waived the need for patient written 
informed consent, as this was a retrospective study. 
RESULTS 
The mean age of PM patients was 60.5 years old (16 pa-
tients were men) and that of DM patients was 54.4 years 
old (15 patients were men). At diagnosis, proximal muscle 
weakness was observed in all PM patients but it was not 
in all DM patients (83.7%). DM-specific typical skin rash 
was presented only in DM patients but not PM patients 
at all. By contrast, elevated serum skeletal muscle enzyme 
levels were detected in all subjects in this study. Electro-
myography (EMG) and muscle biopsy were performed in 
PM patients more frequently than DM patients at diag-
nosis (98.6% vs. 83.7% and 73.3% vs. 51.0%) (Table 1). 
When the 2017 EULAR/ACR criteria were applied to 
72 PM patients, three patients (4.2%) were newly reclas-
sified as non-IIM due to a total score of 5.3 or small-
er. At diagnosis, these three patients were classified as 
probable PM without muscle biopsy, based on proximal 
muscle weakness, elevation of serum creatinine phos-
phokinase (CK) level and abnormal EMG results (Table 
2). Meanwhile, one patient, who was classified as possi-
ble PM, was newly reclassified as probable PM due to 
the presence of dysphagia (Table 2). 
In addition, when the 2017 EULAR/ACR criteria were 
applied to 49 DM patients based on Bohan and Peter 
criteria, eight patients (16.3%) were newly reclassified as 
ADM due to the absence of proximal muscle weakness. 
At diagnosis, eight patients were classified as possible 
DM without muscle biopsy or EMG, based on elevation 
of serum CK level and DM-specific typical skin rash (Ta-
ble 2). Nevertheless, these eight patients with DM could 
clinically be classified as ADM based on the Bohan and 
Peter criteria, despite no comment on ADM. 
The concordance rate of the classification between 
the Bohan and Peter criteria and the 2017 EULAR/ACR 
criteria was 95.8% for PM patients and 83.7% for DM pa-
tients.  Because one patient with possible PM was reclas-
Figure 1. The algorithm for the inclusion of patients with 
polymyositis and dermatomyositis. 
  78 Polymyositis
  59 Dermatomyositis
137 Total
  72 Polymyositis
  49 Dermatomyositis
121 Total
  72 Polymyositis
       55 Definite
       16 Probable
         1 Possible
  49 Dermatomyositis
       41Definite
        0 Probable
        8 Possible
Exclusion due to insufficient medical records
    6 Polymyositis
  10 Dermatomyositis
Table 1. Baseline characteristics of patients with PM and DM based on the classification criteria proposed by Bohan and Peter
Variable Patients with PM (n = 72) Patients with DM (n = 49)
Age, yr 60.5 ± 16.0 54.4 ± 15.0
Male sex 16 (21.3) 15 (30.6)
Muscle weakness 72 (100) 41 (83.7)
Skin manifestation 0 49 (100)
Dysphagia 18 (25.0) 10 (20.4)
Anti-Jo-1 24 (33.3) 10 (20.4)
CK/LDH/LFT elevation 72 (100) 49 (100)
EMG 71 (98.6) 41 (83.7)
Muscle MRI 10 (13.9) 6 (12.2)
Muscle biopsy 55 (73.3) 25 (51.0)
Values are expressed as mean ± SD or number (%). 
PM, polymyositis; DM, dermatomyositis; Anti-Jo-1, antihistidyl tRNA synthetase; CK, creatinine phosphokinase; LDH, lactate 
dehydrogenase; LFT, liver function test; EMG, electromyography; MRI, magnetic resonance imaging. 
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sified as probable PM, one patient was not included in 
the concordance rate analysis. 
DISCUSSION
In this study, we reclassified Korean patients with PM 
and DM, who were classified by the Bohan and Peter 
criteria at diagnosis, the 2017 EULAR/ACR criteria and 
found that three of 72 PM patients were newly reclassi-
fied as non-IIM and eight of 49 DM patients were reclas-
sified as ADM. The concordance rate of the classification 
between the two criteria was 95.8% for PM patients and 
83.7% for DM patients. On the other hand, we compared 
the concordance rates in IIM patients with and without 
the results of the muscle biopsy. PM patients with his-
tological results of the muscle biopsy exhibited a con-
cordance rate of 100%, whereas those without the his-
tological results showed a concordance rate of 80.0% 
between the Bohan and Peter criteria and 2017 EULAR/
ACR criteria. DM patients with the histological results 
of the muscle biopsy exhibited a concordance of 100%, 
whereas those without the histological results showed a 
reduced concordance rate of 52.2% between the two cri-
teria. Therefore, if muscle biopsy could be performed in 
most cases of PM and DM, the clinical significance of the 
Bohan and Peter criteria for clearly classifying patients 
suspected with IIM as PM and DM could be increased. 
A recent study investigated the relationship between the 
expert-assigned and the 2017 EULAR/ACR criteria-as-
signed IIM subtypes. When applying the 2017 EULAR/
ACR criteria to patients with IIM based on the expert 
opinion, they reported that all 37 patients with PM were 
reclassified as PM, whereas three of 57 patients with DM 
were reclassified as PM. The concordance rate of the clas-
sification of the recent study was 100% for PM patients 
and 94.7% for DM patients [12]. However, we could not 
compare the concordance rate of our study with that of 
the recent study, because the expert opinion was not ac-
cording to the Bohan and Peter criteria and furthermore, 
the geographical and ethnic backgrounds were different. 
DM patients without evidence of myositis but with 
DM-specific typical skin rashes, such as heliotrope rash 
or Gottron’s sign or papules based on the Bohan and 
Peter criteria could be clinically classified as ADM. This 
assumption may increase the concordance rate in DM 
patients up to 100%. However, precise attention should 
be paid to the differential diagnosis ADM from DM, as 
ADM is a poor prognostic factor for the concurrence of 
interstitial lung disease in Korean patients with ADM 
[13]. These overall results suggest that the classifica-
tion-accuracy of Bohan and Peter criteria might be not 
inferior to that of the 2017 EULAR/ACR criteria in Kore-
an patients with PM and DM. 
A remarkable change between the two criteria was 
that dysphagia and anti-Jo-1 were included in the 2017 
EULAR/ACR criteria. Among several myositis-specific 
autoantibodies, such as anti-Jo-1, anti-Mi-2, anti-sig-
nal recognition particle (SRP), anti-PL-7 and anti-PL-12, 
only anti-Jo-1 was included [11]. Furthermore, the high-
est score (3.9 without biopsy and 38 with biopsy) was al-
located to the presence of anti-Jo-1. In our study, three 
PM patients were reclassified as non-IIM by the new 
criteria. Anti-Jo-1 was not detected and muscle biop-
sy was not performed in these three patients in whom 
the classification was changed. Considering the high 
concordance rate of the classification and the highest 
score of anti-Jo-1 in the 2017 EULAR/ACR criteria, we 
suggest that the Bohan and Peter criteria should prefer-
entially be applied to a patient suspected of PM without 
DM-specific typical skin rash. And then, if the patient is 
classified as probable PM without both muscle biopsy 
or anti-Jo-1, performing muscle biopsy should be con-
sidered to discern between PM and other IIMs. Mean-
while, although a relatively low score of 0.7 was allocat-
ed to dysphagia, which was newly included in the 2017 
EULAR/ACR criteria, one patient with possible PM was 
reclassified as and promoted to probable PM by the new 
criteria owing to the presence of dysphagia. 
Our study has a merit that we first reclassified Korean 
patients with PM and DM based on the Bohan and Peter 
criteria at diagnosis by the 2017 EULAR/ACR criteria and 
demonstrated that the concordance rate between the 
two criteria was 95.8% for PM patients and 83.7% for DM 
patients. Our study also has an issue that the number of 
patients in this study was too small to represent Korean 
patients due to a retrospective and monocentric study. 
However, we could minimise the inter-centric variation 
and provide the unified the neuromuscular examina-
tion by neurologists based on the same protocol due to a 
monocentric study. Future studies with a larger number 
of IIM patients will afford the more reliable and clearer 
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information on the concordance rate of the classifica-
tion between the Bohan and Peter criteria and the 2017 
EULAR/ACR criteria. 
The Bohan and Peter criteria were comparable to the 
2017 EULAR/ACR criteria for classifying PM and DM in 
Korean patients. Given that the Bohan and Peter criteria 
are convenient in the real clinical settings, we suggest 
that the old criteria should be preferentially applied and 
then performing muscle biopsy should be considered 
in a patient suspected of PM without anti-Jo-1. More-
over, ADM could also clinically be classified by the old 
criteria.
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KEY MESSAGE
1. The concordance rate of the classification be-
tween the Bohan and Peter criteria and the 2017 
European League Against Rheumatism (EU-
LAR)/American College of Rheumatology (ACR) 
criteria was 95.8% for polymyositis (PM) patients 
and 83.7% for dermatomyositis (DM) pa tients. 
2. The Bohan and Peter criteria were comparable 
to the 2017 EULAR/ACR criteria for classifying 
PM and DM in Korean patients.
3. The old criteria should be preferentially applied 
and then performing muscle biopsy should be 
considered in a patient suspected of PM with-
out antihistidyl tRNA synthetase (anti-Jo-1).
